Articles On Oncosil Medical (ASX:OSL)

OncoSil Medical (OSL) enrols the first patient into its randomised clinical study of its namesake OncoSil device to be used in combination with Folfirinox chemotherapy OSL plans to recruit 80 patients across 15 hospital sites in the UK a...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Medical device company OncoSil (ASX:OSL) has announced the findings of an oral presentation at The Mayo Clinic IMPACT Course 2023 by Dr Frank Weilert from Waikato Hospital in New Zealand.

ASX closes 5 points lower, down 0.08% after a day of ups and downs Goldies are the clear winners again, up 1.96% and well ahead of the market Mt Monger does well with a 23% gain to be over +130% for the month   After an early grimace-indu...

ASX 200 benchmark closes 0.11% lower after a fickle day on the bourse Iron ore price drops to five month lows, making (almost) everyone sad Larvotto ends up on top of the Small Caps, adding 61.9% for the day   Aussie markets were a tad me...

OncoSil Medical (OSL) makes further commercial progress in Spain with its namesake OncoSil brachytherapy device for the treatment of pancreatic cancer The company says the first patient treated with OncoSil in Spain has undergone success...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX down, then up, then down even further to -1.4% as bank crisis looms large. XEC Emerging Companies index plummets 1.8% as fear overtakes greed. Goldies are making hay again, XED All Ordinaries Gold up more than 7.0%.   Things have been...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

OncoSil (OSL) treats its first commercial patients with its namesake device at two key treatment centres in the Middle East and Spain The treatment took place at the Wolfson Medical Center in Tel Aviv in Israel and the Clinica Universida...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

OncoSil (OSL) treats its first ten patients with the OncoSil device in SpainSince treating the first patient in April, four hospital sites have now performed the implantation of the OncoSil deviceThe company says it’s proud to have achieved...

OncoSil (OSL) signs a distribution agreement for the sale of its OncoSil device in selected Chinese marketsOSL penned the deal with Hind Wing Company to provide exclusive distribution rights for the sale of the device within Hong Kong, Maca...

Clarity Pharma announced positive results from Phase 1 trial Starpharma brings VIRALEZE to Indonesia Race Oncology has a new CEO   Clarity Pharma (ASX:CU6) announced that its diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER has met all...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ShareCafeThe Week that Was: November 14-18, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so...

ShareCafeOncoSil Medical (ASX: OSL) – Targeted therapy for pancreatic cancer OncoSil Medical Limited (ASX: OSL) Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company’s th...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

OncoSil Medical (OSL) treats its second patient in a locally advanced pancreatic cancer clinical trial The treatment was undertaken in Madrid, where the volunteer underwent a successful resection of a pancreatic tumour using the OncoSil de...

HeraMED’s device is effective for telemedicine in monitoring pregnant women Mesoblast issues strong study results OncoSil announces success in Spain Just-released results from a clinical trial undertaken by Israel’s Sheba Medical Center c...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsius Resources is hot   The ASX 200 and the Emerging Markets (XEC) indices are both trading higher on Monday up about 1.2%, ahead of tomorrow...

Bupa UK Insurance becomes the first health insurance company to provide reimbursement for OncoSil Medical’s (OSL) namesake device Following this milestone, OncoSil will be working with the London Clinic to provide reimbursement with other...

HitIQ and Volpara sign major deals in the US ECS Botanics makes first cannabis flower shipment to NZ Invex to commence Phase III study in Australia Following its extension contract with New Zealand Rugby a couple of weeks ago, HitIQ (ASX:...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Benchmark lifts on uranium, energy gains Small caps on energy and materials Newcomer Southern Palladium nails debut. Nails. It.   The benchmark is higher and the small cap index is a bit higher, but the real action on a lazy winter Wednes...

Highlights The benchmark ASX 200 was trading 0.59% up at 7,400.6 in the first 10 minutes of trading. A strong earnings report from Meta Platforms lifted the beaten down tech shares in the US on Thursday. The energy sector is the top p...

OncoSil Medical (OSL) signs its first commercial agreement in Spain for the OncoSil device with The Hospital Universitario de Fuenlabrada in Madrid The legally binding agreement worth €374,000 (A$553,000) will enable the hospital to treat...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

OncoSil Medical (OSL) places its shares in a trading halt pending the release of a capital raising announcement The medical technology company’s shares will remain in the halt until the earlier of April 29 or when the announcement is relea...

Halo Technologies (HAL) shares have plunged 27.5 per cent since its ASX debut yesterday. The listing came after the company raised more than $36 million through an IPO priced at $1.20 per share. The Australian business offers global s...

Local stocks hit cruise control heading into the Easter break, with steady gains across the ASX in a calm session. The microcap ASX Emerging Companies index rose by around 0.8%, slightly outperforming the big end of town. It followed a soli...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Okay, who poked the S&P/ASX Emerging Companies index (XEC) this morning? Someone woke the sleeping Spinosaurus – the largest carnivorous dinosaur on this planet – that lies at the heart of our beloved small cap thermometer. It started r...

Today is a good day for the OncoSil Medical Ltd (ASX: OSL) share price after the company released news of its pancreatic cancer treatment. The treatment – which comes in the form of a device – has surpassed a major milestone. It has been u...

OncoSil Medical (OSL) reports the company’s first commercial treatment of pancreatic cancer with the company’s flagship OncoSil device in Europe The treatment took place in Madrid, Spain at the Hospital Universitario de Fuenlabrada The dev...

Oncosil’s medical device is being used commercially for the first time in Europe NeuroScientific Biopharma is set to commence Phase 1 clinical trial after a successful toxicology study Medical device company, OncoSil Medical (ASX:OSL), su...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

OncoSil Medical (OSL) receives approval to undertake a fully funded clinical trial of its OncoSil device in Germany The trial will assess the performance of the OncoSil device in a comparison of the combination of standard-of-care (SoC) c...

Highlights OncoSil Medical has secured G-BA approval for a fully funded trial to evaluate its OncoSil device.   Successful results from the clinical trial are anticipated to lead to public insurance reimbursement funding of the devi...

Oncosil’s medical device will be used in a German government funded clinical trial PainChek to expand its technology in New Zealand Oncosil gets green light in Germany Medical device company OncoSil (ASX:OSL) announced that Germany has ap...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The S&P/ASX200 pared earlier losses to finish ~0.2% lower. Wall Street lifted, but my word  — those gains were undermined by an after market bombshell from Facebook’s weird parent company, Meta ($FB), which slumped after totally disresp...

OncoSil Medical’s (OSL) device is approved for innovation funding for hospitals in Germany The German institute for the Hospital Remuneration System granted the OncoSil device with a “Positive Status 1” classification under the innovation...

The ASX 200 Health Index (XHJ) has fallen by 1.26% at the time of writing, compared to the broader index which is down by 0.12%. Medical device company OncoSil Medical (ASX:OSL) surged as high as 25% up today, after its device was granted a...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...